Functional genomics and cancer drug target discovery

被引：0

作者：

Moody, Susan E. ^{[1
,2
,3
,4
,5
]}

Boehm, Jesse S. ^{[4
,5
]}

Barbie, David A. ^{[1
,4
,5
,6
]}

Hahn, William C. ^{[1
,2
,3
,4
,5
,7
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA 02115 USA

[4] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA

[5] MIT, Cambridge, MA 02142 USA

[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[7] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA

来源：

CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2010年 / 12卷 / 03期

关键词：

Cancer; functional genomics; molecular target; oncogene; synthetic lethality; tumor suppressor; RNA INTERFERENCE SCREEN; ACUTE MYELOID-LEUKEMIA; SYNTHETIC LETHAL SCREEN; BETA-CATENIN ACTIVITY; DOUBLE-STRANDED-RNA; FULL-LENGTH HUMAN; CELL LUNG-CANCER; GENETIC SCREEN; COLORECTAL-CANCER; BREAST-CANCER;

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The recent development of technologies for whole-genome sequencing, copy number analysis and expression profiling enables the generation of comprehensive descriptions of cancer genomes. However, although the structural analysis and expression profiling of tumors and cancer cell lines can allow the identification of candidate molecules that are altered in the malignant state, functional analyses are necessary to confirm such genes as oncogenes or tumor suppressors. Moreover, recent research suggests that tumor cells also depend on synthetic lethal targets, which are not mutated or amplified in cancer genomes; functional genomics screening can facilitate the discovery of such targets. This review provides an overview of the tools available for the study of functional genomics, and discusses recent research involving the use of these tools to identify potential novel drug targets in cancer.

引用

页码：284 / 293

页数：10

共 96 条

[1] Chemokine signaling via the CXCR2 receptor reinforces senescence [J].

Acosta, Juan C. ;

O'Loghlen, Ana ;

Banito, Ana ;

Guijarro, Maria V. ;

Augert, Arnaud ;

Raguz, Selina ;

Fumagalli, Marzia ;

Da Costa, Marco ;

Brown, Celia ;

Popov, Nikolay ;

Takatsu, Yoshihiro ;

Melamed, Jonathan ;

di Fagagna, Fabrizio d'Adda ;

Bernard, David ;

Hernando, Eva ;

Gil, Jesus .

CELL, 2008, 133 (06) :1006-1018

[2] Approaches for chemically synthesized siRNA and vector-mediated RNAi [J].

Amarzguioui, M ;

Rossi, JJ ;

Kim, D .

FEBS LETTERS, 2005, 579 (26) :5974-5981

[3] Live-Cell Imaging of Caspase Activation for High-Content Screening [J].

Antczak, Christophe ;

Takagi, Toshimitsu ;

Ramirez, Christina N. ;

Radu, Constantin ;

Djaballah, Hakim .

JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (08) :956-969

[4] Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening [J].

Aza-Blanc, P ;

Cooper, CL ;

Wagner, K ;

Batalov, S ;

Deveraux, QL ;

Cooke, MP .

MOLECULAR CELL, 2003, 12 (03) :627-637

[5] Microarrays of lentiviruses for gene function screens in immortalized and primary cells [J].

Bailey, SN ;

Ali, SM ;

Carpenter, AE ;

Higgins, CO ;

Sabatini, DM .

NATURE METHODS, 2006, 3 (02) :117-122

[6] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[7] Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions [J].

Bartz, Steven R. ;

Zhang, Zhan ;

Burchard, Julja ;

Imakura, Maki ;

Martin, Melissa ;

Palmieri, Anthony ;

Needham, Rachel ;

Guo, Jie ;

Gordon, Marcia ;

Chung, Namjin ;

Warrener, Paul ;

Jackson, Aimee L. ;

Carleton, Michael ;

Oatley, Melissa ;

Locco, Louis ;

Santini, Francesca ;

Smith, Todd ;

Kunapuli, Priya ;

Ferrer, Marc ;

Strulovici, Berta ;

Friend, Stephen H. ;

Linsley, Peter S. .

MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (24) :9377-9386

[8] A large-scale RNAi screen in human cells identifies new components of the p53 pathway [J].

Berns, K ;

Hijmans, EM ;

Mullenders, J ;

Brummelkamp, TR ;

Velds, A ;

Heimerikx, M ;

Kerkhoven, RM ;

Madiredjo, M ;

Nijkamp, W ;

Weigelt, B ;

Agami, R ;

Ge, W ;

Cavet, G ;

Linsley, PS ;

Beijersbergen, RL ;

Bernards, R .

NATURE, 2004, 428 (6981) :431-437

[9] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[10] Role for a bidentate ribonuclease in the initiation step of RNA interference [J].

Bernstein, E ;

Caudy, AA ;

Hammond, SM ;

Hannon, GJ .

NATURE, 2001, 409 (6818) :363-366

← 1 2 3 4 5 6 7 8 9 10 →